[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370808-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370808-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ivabradine-induces-rad51-degradation-potentiating-parp-inhibitor-efficacy-in-nongermline-brca-pathogenic-variant-triplenegative-breast-cancer","Ivabradine induces RAD51 degradation, potentiating PARP inhibitor efficacy in nongermline BRCA pathogenic variant triplenegative breast cancer","","Triple-negative breast cancer (TNBC) is an aggressive subtype without targetable proteins. PARP inhibitors (PARPi) work well in BRCA-mutated disease, but remain less effective in non-germline BRCA–mutated TNBC. This study tests whether inducing “BRCAness” by targeting RAD51, a central homologous recombination factor, can sensitize non-gBRCAm TNBC to PARPi. EGFP-RAD51 reporter assays, viability studies, DNA repair readouts, and ER-stress signaling experiments evaluate combined ivabradine and olaparib effects in vitro and in vivo.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ivabradine-induces-rad51-degradation-potentiating-parp-inhibitor-efficacy-in-nongermline-brca-pathogenic-variant-triplenegative-breast-cancer/370808/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ivabradine-induces-rad51-degradation-potentiating-parp-inhibitor-efficacy-in-nongermline-brca-pathogenic-variant-triplenegative-breast-cancer/370808.png","ImageObject",300,407,{"name":42,"@type":43},"Dipper","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are PARP inhibitors less effective in non-germline BRCA–mutated TNBC?","Question",{"text":63,"@type":64},"PARP inhibitors are effective in BRCA-mutated cancers, but have limited utility in non-germline BRCA–mutated TNBC. The study frames this as an unmet need for improving PARPi performance in non-gBRCAm TNBC.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does ivabradine affect RAD51 and DNA repair in TNBC?",{"text":68,"@type":64},"Ivabradine reduces RAD51 using an EGFP-RAD51 reporter and impairs HR-mediated DNA repair. Mechanistically, it triggers ER stress, activates ATF6, upregulates FBXO24-dependent ubiquitination, and leads to RAD51 degradation and BRCAness.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the evidence that ivabradine potentiates olaparib in vivo?",{"text":72,"@type":64},"Combination treatment with clinical-grade ivabradine (Coralan) and olaparib (Lynparza) produced substantial tumor growth inhibition in xenografts and patient-derived tumor xenografts without notable toxicity. The study confirms the ATF6-FBXO24-RAD51 cascade with chromatin immunoprecipitation and co-immunoprecipitation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370808,1790411226,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Tsoi et al. Journal of Translational Medicine (2025) 23:860  \n[https://doi.org/10.1186/s12967-025-06902-8](https://doi.org/10.1186/s12967-025-06902-8)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nIvabradine induces RAD51 degradation, potentiating PARP inhibitor efficacy in nongermline BRCA pathogenic variant triplenegative breast cancer  \nHoTsoi 1, George Man Hong Leung 1, Ellen Pui Sum Man 1, Chan Ping You 1, Koei Ho Lam Cheung 1, Kelvin Yuen Kwong Chan2, Chun Gong3, Michael Shing Yan Huen4 and Ui Soon Khoo 1*  \nAbstract  \nBackground Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targetable proteins for treatment. PARP inhibitors (PARPi) are effective in BRCA-mutated cancers but have limited utility in non-germline BRCAmutated (non-gBRCAm) TNBC. We hypothesized that inducing BRCAness by targeting RAD51, a key homologous recombination protein, could sensitize non-gBRCAmTNBC to PARPi.  \nMethods EGFP-tagged RAD51 was generated and EGFP signal was monitored for identifying agents that affected RAD51 protein expression and stability. Cell viability was assayed using cell counting kit-8 . Synergism of ivabradine and olaparib was determined using SynergyFinder 3.0. DR-GFP, EJ5-GFP and comet assays were employed to evaluate the degree of DNA repair and damage, respectively. Protein and mRNA levels were determined by western blot and qPCR, respectively. ChIP was used to determine the binding to ATF6 to the promoter of FBXO24 . CoIP was employed to determine the interaction between RAD51 and FBXO24 . Xenografts on nude mice and PDTX were in vivo models for validating the combined effect of ivabradine and olaparib.  \nResults Using an EGFP-RAD51 reporter, we identified ivabradine as a RAD51-reducing agent. In vitro studies with TNBC cell lines demonstrated that ivabradine synergized with PARPi to reduce cell viability (ZIP score > 10), induce apoptosis, and impair HR-mediated DNA repair. This synergy was confirmed in vivo using xenografts and patientderived tumor xenografts, where co-treatment with clinical grade ivabradine (Coralan) and PARPi olaparib (Lynparza) led to substantial tumor growth inhibition without notable toxicity. Mechanistically, ivabradine triggered ER stress, activating ATF6 to upregulate FBXO24-dependent ubiquitination, leading to RAD51 degradation, resulting in the condition of BRCAness. Chromatin immunoprecipitation and co-immunoprecipitation confirmed the ATF6-FBXO24-RAD51 cascade. These findings reveal a novel mechanism by which ivabradine, an FDA-approved cardiac drug, induces BRCAness, by degrading RAD51 via the ATF6-FBXO24 axis, thus, by mimicking HR deficiency hypersensitizes BRCA-proficient TNBC to olaparib.  \n*Correspondence: Ui Soon Khoo uskhoo@hku.hk  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/.  \nTsoi et al. Journal of Translational Medicine (2025) 23:860 Page 2 of 20  \nConclusion This study highlights the translational potential of repurposing ivabradine as a therapeutic strategy for non-gBRCAmTNBC. By addressing a critical unmet need of this aggres","cbCaijrQOHuztbWv","https://ap.wps.com/l/cbCaijrQOHuztbWv","pdf",10511445,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n## Background","[{\"question\":\"Why are PARP inhibitors less effective in non-germline BRCA–mutated TNBC?\",\"answer\":\"PARP inhibitors are effective in BRCA-mutated cancers, but have limited utility in non-germline BRCA–mutated TNBC. The study frames this as an unmet need for improving PARPi performance in non-gBRCAm TNBC.\"},{\"question\":\"How does ivabradine affect RAD51 and DNA repair in TNBC?\",\"answer\":\"Ivabradine reduces RAD51 using an EGFP-RAD51 reporter and impairs HR-mediated DNA repair. Mechanistically, it triggers ER stress, activates ATF6, upregulates FBXO24-dependent ubiquitination, and leads to RAD51 degradation and BRCAness.\"},{\"question\":\"What is the evidence that ivabradine potentiates olaparib in vivo?\",\"answer\":\"Combination treatment with clinical-grade ivabradine (Coralan) and olaparib (Lynparza) produced substantial tumor growth inhibition in xenografts and patient-derived tumor xenografts without notable toxicity. The study confirms the ATF6-FBXO24-RAD51 cascade with chromatin immunoprecipitation and co-immunoprecipitation.\"}]","Ivabradine induces RAD51 degradation, potentiating PARP inhibitor efficacy in nongermline BRCA pathogenic variant triplenegative breast cancer | PDF",1790190453,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf7425866f8ddaa2472e1ec2337a753a.webp",983,1310,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87c148a72c8698c1b41484cbfee43fec.webp",982,1309,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d47d0716f2f1bd7d9ed120dbd6fd78f.webp",981,1308,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc155e2ef5400c18b9c2e40b8a207cda.webp",980,1306]